AtriCure downgraded to Hold by Freedom Capital Markets with $57 price target

Freedom Capital Markets downgraded AtriCure (ATRC) to Hold and set a price target of $57.00, implying a 6.4% upside from the previous close. The downgrade was based on concerns over the stock's overvaluation relative to the broader medtech sector.